Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered?
- 1 March 2001
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (3), 669-674
- https://doi.org/10.1161/01.str.32.3.669
Abstract
Background and Purpose—The results of phase III trials of neuroprotective drugs for acute ischemic stroke have been disappointing. We examine the question of whether these trials may have been underpowered.Keywords
This publication has 6 references indexed in Scilit:
- Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Comprehensive Decision ModelJournal of Clinical Epidemiology, 1999
- Determining Clinically Important Differences in Health Status MeasuresPharmacoEconomics, 1999
- Cost-effectiveness of tissue plasminogen activator for acute ischemic strokeNeurology, 1998
- The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting ResultsAnnals of Internal Medicine, 1994
- Statistical Power, Sample Size, and Their Reporting in Randomized Controlled TrialsJAMA, 1994